Prespecified secondary oues were as follows: all-cause mortality; fatal and nonfatal stroke; H. and bined CVD . In additi all-cause mortality was classified into CVD and non-CVD causes. Statistical Analysis Baseline characteristics werepared across year potassium concentrations using the z test for continuous variables and contin-gency table Gynostemma Extract analysis for categorical variables. Cumulative event rates were calculated using the Kaplan-Meier method. 0 Cox proportional hazards regression models were used topare hypokalemia/normokalemia and hyperkale-mia/normokalemia while adjusting for a ra s history of diabetes mellit CHD and atherosclerotic C cigarette smoki baseline systolic BP and and estimated year glomerular filtration rate.
To account for the possible differences in follow-up BP and Cox PH regression analyses with time-dependent covariates were also performed. The PH assumption was examined with log-log plots and Schoen-feld residual analysis . the assumption was violated on for HF among C participan and a logistic model was used to obtain odds ratios and CIs. Heterogeneity of effects raltegravir clinical trial in subgroups was examined ALLHAT enrolled men and women aged 5 years with by testing for treatment-covariate interaction with the Cox PH hypertension and additional CVD risk factor; 5 of participants were black; 9 were Hispanic. Recruitment was aplished between February and January . Active follow-up ended in March . Included in this report are normokalemic participants assigned to C, A, or L who had potassium measurements at baseline and year .
Participants were grouped into strata according to their year K lev and postyear oues over an average of years werepared. All of the participants gave written informed conse all of the centers obtained institutional review board approv gsk3b inhibitor and the trial was monitored by a National Hea Lu and Blood Institute “appointed data and safety monitoring board. Treatment Unless the drug regimen required tapering for safety reaso individuals continued any previous antihypertensive medications until they received their randomized study drug. Participants were randomly assigned to or L regression model using P , indicating statistical significance. Howev given the many multivaria subgro and interaction analyses perform statistical significance at this level should be interpreted with caution.
Results The study cohort was derived from ALLHAT partic-ipants randomized to C, A, or L . It wasposed of partici-pants who had normal baseline K values and valid year value. of the had hypokalem had normokalem and had hyperkalemia at year . Baseline characteristics were similar between this Daptomycin solubility and the overall ALLHAT cohort . Inparison with normokalemic subjec those who became hypokalemic were Downloaded from hyper.ahajournals/ at New York University/ Medical Center New York on March 7, Alderman ALLHAT Serum Potassium and Cardiovascular Events Table . Cumulative No. of Even -Y Kaplan-Meier Event Rates per , Cox Proportional H Corresponding 5 C and P Values for Hypokalemia and Normal Y K Subgroups Within Drug Groups No. of Events -y Rate per Oue by Unadjust Adjust Drug Group indicates amlodipine; C, chlorthalidone; CC bined cardiovascular gold disease.